Deep brain stimulation: revision 1 to 2

Revision 1

Revision 2

categories: ["cybernetics"]

tags: ["neuromodulation", "parkinsons", "implants", "psychiatry", "closed-loop", "neuroethics"]

summary: "A surgical therapy in which implanted electrodes deliver continuous electrical pulses to specific deep brain structures to suppress the symptoms of movement and psychiatric disorders."

summary: "A surgical therapy in which implanted electrodes deliver continuous electrical pulses to specific deep brain structures to suppress the symptoms of movement and psychiatric disorders."

updated: "2026-07-27"

updated: "2026-10-29"

humanEvidence: "Randomized trials in adults with Parkinson's disease report large gains in mobility and quality of life against best medical therapy, and the device is in routine clinical use; two randomized trials in depression were halted for futility."

humanEvidence: "Randomized trials in adults with Parkinson's disease report large gains in mobility and quality of life against best medical therapy, and the device is in routine clinical use; two randomized trials in depression were halted for futility."

access: "Approved for Parkinson's disease, essential tremor, dystonia and drug-resistant epilepsy, reimbursed by many high-income systems, and delivered only at specialist centres; psychiatric use is investigational beyond a US exemption for OCD."

access: "Approved for Parkinson's disease, essential tremor, dystonia and drug-resistant epilepsy, reimbursed by many high-income systems, and delivered only at specialist centres; psychiatric use is investigational beyond a US exemption for OCD."

reversibility: "difficult"

{ "label": "Modern technique from", "value": "1987, Grenoble" },

{ "label": "Key figures", "value": "Alim-Louis Benabid, Pierre Pollak" },

{ "label": "Common targets", "value": "STN, GPi, VIM thalamus" },

{ "label": "Typical parameters", "value": "130–185 Hz, 60–90 µs" },

{ "label": "Typical parameters", "value": "130-185 Hz, 60-90 µs" },

{ "label": "First US approval", "value": "1997 (tremor)" },

{ "label": "Patients treated", "value": "150,000+ worldwide" },

{ "label": "Readiness", "value": "Routine clinical care" }

**Deep brain stimulation** (DBS) is the delivery of continuous electrical pulses through electrodes

implanted in specific subcortical structures, controlled by a pulse generator placed under the skin

of the chest. It is the most widely used implanted neurotechnology after the

of the chest. It is the most widely used implanted neurotechnology after the [[cochlear-implant]],

[[cochlear-implant]], and it is unusual among the technologies covered on this wiki in being both

and it is unusual among the technologies covered on this wiki in being both routine and poorly

routine and poorly understood: DBS reliably suppresses the motor symptoms of Parkinson's disease

understood: DBS reliably suppresses the motor symptoms of Parkinson's disease without a settled

without a settled account of why.

account of why.

```figure

{"key": "dbs-electrode-placement", "caption": "Lead placement reconstructed against the surrounding structures. A few millimetres decide which circuit is stimulated."}

{"key": "dbs-electrode-placement", "caption": "Lead placement reconstructed against the surrounding structures. A few millimetres decide which circuit is stimulated."}

A quadripolar or segmented lead, roughly 1.3 mm in diameter, is placed stereotactically with

millimetre accuracy, often with the patient awake so that clinical response and side effects can be

tested intraoperatively. The lead is tunnelled under the scalp and connected to an implanted pulse

generator. Stimulation is typically delivered at 130–185 Hz with pulse widths of tens of

generator. Stimulation is typically delivered at 130-185 Hz with pulse widths of tens of

microseconds, and each contact can be turned on independently, allowing a clinician to steer the

field away from structures that produce side effects.

The mechanism is contested. High-frequency stimulation was first assumed to inhibit the target,

because its effects resemble those of a lesion. The evidence now points elsewhere. Stimulation

excites axons more readily than cell bodies, so a high-frequency train imposes a regular,

information-free firing pattern on the output pathway — an "informational lesion" that overwrites

information-free firing pattern on the output pathway. The result is an "informational lesion" that

pathological bursting rather than silencing it. Antidromic activation of cortical afferents,

overwrites pathological bursting rather than silencing it. Antidromic activation of cortical

modulation of the wider cortico-basal-ganglia loop, and effects on astrocytes and local blood flow

afferents, modulation of the wider cortico-basal-ganglia loop, and effects on astrocytes and local

all contribute. What DBS does not do is restore normal circuit function, and this matters

blood flow all contribute. DBS does not restore normal circuit function, and this matters

clinically: it treats symptoms driven by abnormal network dynamics and does nothing for the

underlying degeneration.

```timeline

[

  { "year": "1950s–1960s", "title": "Stereotactic stimulation explored", "text": "Neurosurgeons use intraoperative stimulation to localize targets before making destructive lesions, and a handful of chronic stimulation experiments are attempted for pain and psychiatric illness." },

  { "year": "1950s-1960s", "title": "Stereotactic stimulation explored", "text": "Neurosurgeons use intraoperative stimulation to localize targets before making destructive lesions, and a handful of chronic stimulation experiments are attempted for pain and psychiatric illness." },

  { "year": "1987", "title": "Chronic thalamic stimulation for tremor", "text": "Alim-Louis Benabid and Pierre Pollak in Grenoble report that chronic high-frequency stimulation of the ventral intermediate thalamus suppresses tremor as effectively as thalamotomy, and is reversible and adjustable." },

  { "year": "1987", "title": "Chronic thalamic stimulation for tremor", "text": "Alim-Louis Benabid and Pierre Pollak in Grenoble report that chronic high-frequency stimulation of the ventral intermediate thalamus suppresses tremor as effectively as thalamotomy, and is reversible and adjustable." },

  { "year": "1997", "title": "First US approval", "text": "The FDA approves thalamic stimulation for essential tremor and parkinsonian tremor." },

  { "year": "1997", "title": "First US approval", "text": "The FDA approves thalamic stimulation for essential tremor and parkinsonian tremor." },

  { "year": "2002", "title": "Subthalamic and pallidal targets approved", "text": "Approval extends to the subthalamic nucleus and globus pallidus interna for advanced Parkinson's disease, the indication that now accounts for most implants." },

  { "year": "2002", "title": "Subthalamic and pallidal targets approved", "text": "Approval extends to the subthalamic nucleus and globus pallidus interna for advanced Parkinson's disease, the indication that now accounts for most implants." },

  { "year": "2003–2009", "title": "Dystonia and OCD", "text": "Humanitarian device exemptions cover dystonia and, later, treatment-resistant obsessive-compulsive disorder." },

  { "year": "2003-2009", "title": "Dystonia and OCD", "text": "Humanitarian device exemptions cover dystonia and, later, treatment-resistant obsessive-compulsive disorder." },

  { "year": "2013–2017", "title": "Depression trials fail", "text": "Two industry-sponsored randomised trials of DBS for treatment-resistant depression are halted for futility, chilling psychiatric applications for several years." },

  { "year": "2013-2017", "title": "Depression trials fail", "text": "Two industry-sponsored randomised trials of DBS for treatment-resistant depression are halted for futility, chilling psychiatric applications for several years." },

  { "year": "2018", "title": "Epilepsy indication", "text": "Stimulation of the anterior nucleus of the thalamus is approved in the United States for drug-resistant focal epilepsy." },

  { "year": "2018", "title": "Epilepsy indication", "text": "Stimulation of the anterior nucleus of the thalamus is approved in the United States for drug-resistant focal epilepsy." },

  { "year": "2020s", "title": "Sensing and adaptive systems", "text": "Pulse generators capable of recording local field potentials reach the market, and the first commercial closed-loop systems that adjust stimulation to beta-band activity are cleared in Europe and the United States in 2025." }

  { "year": "2020s", "title": "Sensing and adaptive systems", "text": "Pulse generators capable of recording local field potentials reach the market, and the first commercial closed-loop systems that adjust stimulation to beta-band activity are cleared in Europe and the United States in 2025." }

]

Drug-resistant epilepsy is treated with thalamic stimulation, and a separate class of responsive

neurostimulation devices detects seizure onset from cortical electrodes and delivers stimulation

only when a pattern is recognized — closer in architecture to a

only when a pattern is recognized. In architecture these devices are closer to a

[[brain-computer-interface]] than to conventional DBS.

## Psychiatric applications

Psychiatric DBS is the field's cautionary tale and its most interesting open question. Two

industry-sponsored randomised trials of stimulation for treatment-resistant depression, one

targeting the subcallosal cingulate and one the ventral capsule/ventral striatum, were stopped

targeting the subcallosal cingulate and one the ventral capsule/ventral striatum, were stopped after

after interim analyses indicated they would not separate from sham.[^holtzheimer2017] Open-label

interim analyses indicated they would not separate from sham.[^holtzheimer2017] Open-label follow-up

follow-up of subcallosal cingulate patients nonetheless reported durable response over years in a

of subcallosal cingulate patients nonetheless reported durable response over years in a majority of

majority of a small cohort, suggesting that the failures reflected trial design, target

a small cohort, suggesting that the failures reflected trial design, target localization, and the

localization, and the slow time course of antidepressant response rather than a null effect.

slow time course of antidepressant response rather than a null effect.

Two developments revived the area. Tractography-guided targeting individualizes the electrode

Two developments revived the area. The first, tractography-guided targeting, fits the electrode

position to a patient's own white-matter bundles rather than to atlas coordinates. And a

position to a patient's own white-matter bundles rather than to atlas coordinates. The second was a

single-patient demonstration used a chronically implanted sensing-and-stimulation device to identify

single-patient demonstration that used a chronically implanted sensing-and-stimulation device to

a personal biomarker of depressed state in the amygdala and trigger ventral striatum stimulation

identify a personal biomarker of depressed state in the amygdala and trigger ventral striatum

only when it appeared, an approach that borrows directly from [[neural-decoding]].[^scangos2021]

stimulation only when it appeared, an approach that borrows directly from

That result involves one participant. A pivotal trial in treatment-resistant depression is under

[[neural-decoding]].[^scangos2021] That result involves one participant. A pivotal trial in

way as of 2026; obsessive-compulsive disorder remains approved under a humanitarian exemption with a

treatment-resistant depression is under way as of 2026. Obsessive-compulsive disorder remains

modest evidence base. Treatment-resistant depression draws every available modality, down to the

approved under a humanitarian exemption with a modest evidence base. Treatment-resistant depression

drug-plus-psychotherapy protocols described under [[psychedelic-therapy]], and the recurring

draws every available modality, down to the drug-plus-psychotherapy protocols described under

difficulty is common to all of them: separating what a treatment does from what a patient who knows

[[psychedelic-therapy]], and the recurring difficulty is common to all of them: separating what a

they are being treated reports.

treatment does from what a patient who knows they are being treated reports.

## Adaptive stimulation

Conventional DBS runs open loop: fixed parameters, day and night, regardless of what the brain is

doing. Adaptive DBS uses the implanted lead as a sensor, extracting a control signal — most often

doing. Adaptive DBS uses the implanted lead as a sensor, extracting a control signal and modulating

power in the beta band, 13–30 Hz, which correlates with rigidity and bradykinesia in Parkinson's

stimulation amplitude in response. The signal is most often power in the beta band (13-30 Hz), which

disease — and modulating stimulation amplitude in response. Early crossover studies showed that

correlates with rigidity and bradykinesia in Parkinson's disease. Early crossover studies showed

adaptive stimulation could match or exceed continuous stimulation while delivering substantially

that adaptive stimulation could match or exceed continuous stimulation while delivering

less total current, which reduces stimulation-induced dyskinesia and speech disturbance and extends

substantially less total current, which reduces stimulation-induced dyskinesia and speech

battery life.[^little2013]

disturbance and extends battery life.[^little2013]

Commercial sensing generators arrived in 2020, and closed-loop control reached the market in 2025.

The engineering constraints are the interesting part: the stimulation artefact swamps the signal

The engineering difficulties are that the stimulation artefact swamps the signal being sensed, that

being sensed, biomarkers drift, and a controller that misreads state can oscillate. These are the

biomarkers drift, and that a controller which misreads state can oscillate. These are the same

same problems that limit any chronic implanted decoder, and progress here transfers directly to

problems that limit any chronic implanted decoder, and progress here transfers directly to

[[neuroprosthetics]] more broadly.

## Effects on personality and agency

## Limitations and risks

Intracranial haemorrhage occurs in a small percentage of implantations and is the most serious

surgical complication. Hardware problems — infection requiring explantation, lead fracture or

surgical complication. Hardware problems, such as infection requiring explantation, lead fracture or

migration, skin erosion over the connector — are more common than brain injury and account for much

migration, and skin erosion over the connector, are more common than brain injury and account for

of the reoperation burden. Stimulation-induced side effects include dysarthria, paraesthesia, gait

much of the reoperation burden. Stimulation-induced side effects include dysarthria, paraesthesia,

freezing, and eyelid apraxia; most are reversible by reprogramming, which is itself a labour-intensive

gait freezing, and eyelid apraxia; most are reversible by reprogramming, which is itself a

process requiring an expert clinician and, historically, many hours of trial and error.

labour-intensive process requiring an expert clinician and, historically, many hours of trial and

error.

DBS does not slow disease progression. Axial symptoms — postural instability, freezing of gait,

DBS does not slow disease progression. Axial symptoms (postural instability, freezing of gait,

speech and swallowing difficulty — respond poorly and continue to worsen, and only a

speech and swallowing difficulty) respond poorly and continue to worsen, and only a

disease-modifying approach such as dopaminergic cell replacement from

[[induced-pluripotent-stem-cells]] would address the underlying loss. Cost and the requirement

[[induced-pluripotent-stem-cells]] would address the underlying loss. Cost and the requirement for a

for a specialist centre restrict access sharply, and the geographic distribution of implantation

specialist centre restrict access sharply, and the geographic distribution of implantation rates

rates tracks health-system wealth rather than disease burden, an instance of the pattern examined in

tracks health-system wealth rather than disease burden, an instance of the pattern examined in

[[access-and-inequality]].

## Outlook

of chronic intracranial recordings, a data resource with no precedent in human neuroscience and

obvious implications for [[mental-privacy]]. Directional leads and patient-specific field models

built from a recipient's own imaging, a clinical instance of the approach described under

[[human-digital-twins]], are making programming semi-automatic. And non-invasive alternatives are

[[human-digital-twins]], are making programming semi-automatic. Non-invasive alternatives,

eroding the market at the margins: magnetic-resonance-guided focused ultrasound already ablates the thalamic tremor target

meanwhile, are eroding the market at the margins: magnetic-resonance-guided focused ultrasound

without an incision, and low-intensity variants under [[non-invasive-neuromodulation]] aim to

already ablates the thalamic tremor target without an incision, and low-intensity variants under

modulate deep structures reversibly.

[[non-invasive-neuromodulation]] aim to modulate deep structures reversibly.

The unresolved scientific question is whether DBS can be made specific. Present electrodes excite

every axon within a radius, regardless of type or projection target. Techniques such as

that method is in the eye; reaching a deep brain structure the same way would require gene delivery

to a defined population and a light source implanted beside it. Whether an electrical device can

approach that selectivity, or whether specificity requires a biological intervention, determines how

far DBS can extend beyond the movement disorders it currently treats — and whether the technique

far DBS can extend beyond the movement disorders it currently treats. It also decides whether the

ever has anything to offer the elective modification of healthy brains discussed under

technique will ever have anything to offer the elective modification of healthy brains discussed

[[human-enhancement]], which on present evidence it does not.

under [[human-enhancement]]; on present evidence it does not.

## See also